Eflornithine (IWILFIN) formal purchasing channels at home and abroad and purchasing guide

Eflornithine (IWILFIN) is an oral drug used to treat specific hereditary metabolic diseases or rare diseases. It is not currently on the market in China, so domestic regular pharmacies and medical institutions cannot provide this drug. Since the drug has not been approved for marketing in China and is not included in the medical insurance system, domestic patients cannot purchase or reimburse it through conventional channels. For patients who urgently need the drug, it can only be obtained through formal overseas channels and must strictly abide by international drug purchase regulations.

In overseas markets, the original drug of eflornithine is already on the market. The specifications are usually 192mg*100 tablets, and each box sells for more than 10,000 US dollars. Due to the high price, patients must confirm the supplier's qualifications and the authenticity of the medicine when choosing to purchase, to ensure that the medicine they purchase meets international quality standards. At the same time, transportation and customs clearance processes also need to comply with laws and regulations of various countries to ensure that drugs remain safe and effective during transportation.

Currently, there are no generic drugs of eflornithine on the market, which means that patients can almost only choose original drugs when purchasing drugs overseas, and cannot obtain them through more economical generic drugs. Patients and their families should fully understand the storage conditions, usage methods and potential adverse reactions of the drugs before purchasing them, and formulate a reasonable medication plan under the guidance of a professional doctor to avoid risks caused by improper medication.

Generally speaking, the purchase channels for eflornithine at home and abroad are limited. Domestic patients need to rely on formal overseas channels and pay attention to drug authenticity, transportation safety and professional guidance. If the drug is approved for marketing in China in the future, it will greatly improve patients' drug accessibility while reducing the economic burden and drug purchase risks.

Reference link:https://www.drugs.com